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Background: Migraine is a complex disease whose physiopathological mechanisms are still not completely
revealed.
Findings: We describe an unusual case, not yet described in literature, of a patient who reported migraine
remission, but still presented aura attacks, since starting a therapy with Warfarin.
Conclusions: This case report brings out new questions on the role of the coagulation, especially the blood
coagulation pathway, in migraine with aura pathogenesis, and on the possibility to use vitamin K synthesis
inhibitors, Warfarin or new generation drugs, as possible therapy to use in migraine prophylaxis.
Keywords: Anticoagulant drugs, Aura, Coagulation, MigraineIntroduction
Migraine is a complex disease whose physiopathological
mechanisms are still not completely revealed, despite the
numerous improvements that have been achieved lately
in research (Edvinsson & Uddman 2005). A possible
connection between migraine and stroke was described
(Weinberger 2007). The risk of developing a stroke is
higher in patients suffering from migraine with aura
than without aura; a possible explanation for this associ-
ation could be an hypercoagulable state (Corral et al.
1998; Moschiano et al. 2004). There are few cases
reported in literature in which a substantial reduction of
migraine attacks is observed during the use of vitamin K
antagonists, but in none of these studies a comparison
has been done between patients with migraine and mi-
graine with aura episodes (Maggioni et al. 2012). We
present an unusual case, not yet described in literature,
of a patient who reported migraine remission but still
presented aura attacks since starting a therapy with
Warfarin. We discuss the possible role of anticoagulant
in migraine prophylaxis and the implications of the
blood coagulation pathway in migraine pathogenesis.* Correspondence: russomdstudent@libero.it
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On January 2012, a 31-year-old patient came to the
Modena headache outpatients clinic with his mother (54
years old). His mother was diagnosed with migraine with
aura, according to criteria of the International Headache
Classification (ICH2 2004), complied by the Inter-
national Headache Society (IHS) and who was not re-
sponsive to pharmacological therapy starting from
adolescence. His family medical history reported that
also his father (60 years old), and his two siblings (his
sister, 28 years old, and his brother, 17 years old) were
diagnosed with migraine with aura (ICH2 2004), poor
responsive to pharmacological therapy. Our patient was
the only family member who presented only 4 migraine
attacks with visual aura attacks, with the same clinical
presentation as his family. These episodes appeared at
the age of 16, recurrent monthly and with spontaneous
remission. From the interview it emerged that he has
been in therapy with Warfarin since he was 17, after a
surgical procedure for the substitution of his aortic valve
with a mechanical one. The native valve was insufficient
because of an untreated rheumatic fever that he had in
his childhood. Furthermore, we surprisingly learned that,
once he had started Warfarin therapy, approximately
once a month he presented visual aura without the fol-
lowing migraine attack. For this reason we decided to
re-evaluate the patient after a week. In this occasion we
examined all his clinical reports before the cardiacOpen Access article distributed under the terms of the Creative Commons
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pothesis of a secondary cause for his previous migraine
attacks; also, we confirmed that he suffered from mi-
graine with aura, according to ICH2 2004. Also, we
didn’t find any abnormality on physical and psycho-
logical examination, brain MRI and routine blood tests.
Eventually, we examined more carefully the patient
regarding his coagulative state. He was evaluated for
antithrombin 3, plasminogen, protein C and S, pro-
thrombin time, activated partial thromboplastin time,
factor V-Leiden, von Willebrand factor ristocetin cofac-
tor activity, antinuclear antibody, serum lactic and
pyruvic acid, lupus anticoagulant, antiphospholipid anti-
bodies, factor II and methylenetetrahydrofolate reduc-
tase and homocysteine. We didn’t find anything beyond
the normal range, beside his value of INR of 2.64, due to
his Warfarin therapy.
Discussion
Current molecular and functional studies suggest a way
to incorporate the different aspects into an integrated
hypothesis as neurovascular headaches (Edvinsson &
Uddman 2005). There are evidences that a prothrombo-
tic tendency may be involved in migraine pathogenesis,
particularly in patients with migraine with aura and
patients with migrainous stroke (Weinberger 2007;
Corral et al. 1998; Moschiano et al. 2004). In the last 15
years, the possible role of coagulation defects in mi-
graine patients during attacks and in the intercritical
phase has partially been investigated, and some altera-
tions have been discovered, such as resistance to activate
protein C due to Factor V Leiden mutation, factor II
20210 mutation, factor V 1692 mutation, antithrombin,
protein C, and protein S deficiencies, elevated factor VIII
levels and homocysteinemia (Maggioni et al. 2012;
Hering-Hanit et al. 2001). Furthermore, in literature,
many cases are described in which patients reported mi-
graine remission or mayor improvements after starting a
Warfarin therapy for a different cause; in these studies it
was not evaluated the different patient’s answer in mi-
graine with or without aura (Teber et al. 2011). We
present the unusual case, not yet described in literature,
of a patient who reported migraine remission but still
presented aura attacks with a monthly frequency since
starting a therapy with Warfarin after a surgical proced-
ure of aortic valve substitution. The fact that he still
presented aura attacks is very important, because coagu-
lation defects are nowadays considered more relevant in
the pathogenesis of migraine with aura than without
(Edvinsson & Uddman 2005; Weinberger 2007; Corral
et al. 1998; Moschiano et al. 2004); moreover, our patient
didn’t have any coagulation deficit. This might invite to
a careful consideration on the effective role of the blood
coagulation pathway on migraine with and without aurapathogenesis. This last hypotesis is reinforced consider-
ing the fact that our patient is the only family member
who experienced a complete remission of migraine
attacks, with only aura episodes. Indeed, the other four
components of his family, that in this case we can con-
sider as controls, kept suffering from migraine with aura
attacks, and all of them are poor responsive to pharma-
cological therapy. Given the high ratio between risks and
benefits with the dosage that our patient was using to
obtain an INR between 2 and 3, several authors sug-
gested to carry on observational studies with Warfarin
with dosage that can make patients achieve an INR only
slightly beyond 1.2, but in literature the only double-
blind-trial with acenocoumarol at low dosage failed to
demonstrate the usefulness in migraine prophylaxis
(Wammes-van der Heijden et al. 2005). Currently,
experiments with new anticoagulant drugs that might
both answer on the possible role of blood coagulation
pathway on migraine pathogenesis and that might be
used as prophylactive therapy are taking place (Ahrens
et al. 2010; Mavrakanas & Bounameux 2011). Also
changes of global hemodynamic after aortic-valve re-
placement could be considered on migraine with and
without aura outcome. Further studies are needed to as-
sess the exact role of the blood coagulation pathway in
the pathogenesis of migraine with and without aura; the
role of Warfarin in the improvement of migraine prog-
nosis and the possible different reactions to Warfarin
between patients with migraine with and without aura.
Also, we can consider the use of other anticoagulant
drugs that have an effect on the blood coagulation path-
way but with a better pharmacokinetic and pharmacody-
namic profile.
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